Mutant KRAS is a well-known oncogenic driver and has remained undruggable for many decades. The development of pan-KRAS inhibitors that target a broad range of mutations is a promising approach to cancer treatment.
At the ongoing AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 in Boston, Bridgebio Oncology Therapeutics Inc. (BBOT) presented data on BBO-11818, a potent and selective KRAS inhibitor with activity against several KRAS mutants both in active (ON) and inactive (OFF) forms.
Adoptive cell therapy represents a major step forward in treating hematological cancers. Among its different approaches, chimeric antigen receptor natural killer (CAR-NK) cells are drawing growing interest.
During the first poster session of the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Boston, several presentations highlighted novel strategies that move beyond traditional antibody-drug conjugate (ADC) payloads and targets.
A technology that combines transcriptomic data and AI enables a novel approach to drug discovery based on the state of cells, how they behave and which genes they express. The Drugreflector model, developed by scientists at Cellarity Inc., learns from gene expression profiles and predicts which compounds could induce beneficial changes in that cellular state to develop a treatment.
Jiangsu Hengrui Pharmaceuticals Co. Ltd.; Shanghai Hengrui Pharmaceutical Co. Ltd. have synthesized antibody-drug conjugates (ADCs) comprising a claudin 6 (CLDN6)-targeting antibody linked to cytotoxic drug through linker. They are described as potentially useful for the treatment of ovarian cancer.
Merck KGaA has reported proteolysis targeting chimera (PROTACs) comprising an E3 ubiquitin ligase-binding moiety covalently linked to mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1)-targeting moiety. They are described as potentially useful for the treatment of cancer.
The enzyme PARP1 helps repair single-stranded DNA breaks, and its inhibition shows antitumor efficacy in ovarian, breast, prostate and pancreatic cancers involving mutations in BRCA1 or BRCA2. However, resistance to PARP1 inhibition is a major problem.
Esophageal cancer is among the most lethal cancers with a high mortality rate worldwide. Chinese researchers have explored the potential link between long intergenic non-protein coding RNA 1354 (LINC01354) and esophageal cancer.
RSS
